Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$10.1MCash on Hand
3.9mo Cash Runway
Follow SKYE by emailGet an email when SKYE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SKYE, unsubscribe in one click. Privacy
📣 What SKYE Says Is Next
in 2026 · “Target engagement Phase 2 – Initiation planned in 2026”
Company press release, Aug 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Legal A jury unanimously ruled for Skye Bioscience on Nov 10, 2026 in a former employee's whistleblower and retaliation suit; judgment is expected, and the plaintiff may file post-trial motions or appeal. The filing also covers the proposed acquisition of Redx Pharma Limited. Form 8-K · SEC filing
Sep 11, 2026 ·
Leadership CFO John P. Sharp resigned effective September 8, 2026, with no disagreement with the company or auditors. CEO Punit Dhillon was named principal financial and accounting officer. Nasdaq confirmed the company regained compliance with the $1.00 minimum bid price. Form 8-K · SEC filing
Aug 24, 2026 ·
Financing Entered a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. for an equity line of up to $22,000,000, reduced by any Funded PIPE Amount above $103,000,000, with purchases at the lesser of the PIPE Price or Market Price, but not below a 10% discount to the PIPE Price. Form 8-K · SEC filing
Aug 20, 2026 ·
Listing Skye Bioscience's reverse stock split becomes effective at 12:01 am New York time on August 24, 2026, with split-adjusted trading on Nasdaq at market open that day under the existing SKYE ticker and a new CUSIP of 83086J309. Form 8-K/A · SEC filing
Aug 19, 2026 ·
Listing Skye Bioscience received a Nasdaq notice that its stockholders' equity was ($497,307) as of June 30, 2026, below the $2,500,000 minimum. The stock continues trading, and a compliance plan is due October 2, 2026. Form 8-K · SEC filing
Aug 14, 2026 ·
Deal Skye Bioscience agreed to acquire UK-based Redx Pharma via a scheme of arrangement, with the combined company to be renamed Fibrx Therapeutics and listed on Nasdaq. Concurrent financings total about $125 million gross, including a $68 million PIPE and a $36 million Redx Series A. Expected closing is Q4 2026. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2026 · Phase 2 · Active Trial · Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SKYE holds $10.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.8M/quarter from operations,
an estimated runway of 3.9 months at that rate (BioRadar estimate, not company guidance).
Share count 4,423,469 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SKYE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SKYE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.